Medical Research
(H46Z)
IRS Verified
DX Registered
990 on File
SCLERODERMA RESEARCH FOUNDATION
Financial strength (30%)
76/100
Reliability (20%)
55/100
Effectiveness (25%)
81/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Mission Statement
The mission of the Scleroderma Research Foundation (SRF) is to fund and facilitate the most promising, highest quality research aimed at improved therapies and, ultimately, a cure for scleroderma.
Financial Overview — FY 2025
$13.1M
Total Revenue
$10.3M
Total Expenses
$16.9M
Net Assets
10
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
91.0%
Fundraising Efficiency
1042.4%
Operating Reserve
19.63x
Liability-to-Asset
60.0%
Revenue Diversification
45.0%
Executive Compensation
$838K
Compared with Peers
FY 2025
Compared with 35 similar organizations
(United States, Medical Research, $10M–$100M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
91.0% | 82.0% |
P10P90
|
Top quarter |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
3.4% | 9.0% |
P10P90
|
Top quarter |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
5.6% | 0.2% |
P10P90
|
Below median |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
1042.4% | 1042.4% |
P10P90
|
Below median |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
19.6 mo | 17.6 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
60.0% | 22.9% |
P10P90
|
Bottom quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
45.0% | 84.9% |
P10P90
|
Top quarter |
|
Revenue growth
Year over year revenue growth
|
7.9% | 9.8% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
7.3% | 6.0% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
21.4% | 4.2% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $13.1M | $10.3M | $16.9M | 91.0% | 10 |
| 2024 | $12.2M | $9.6M | $14.1M | 88.8% | 9 |
| 2023 | $8.4M | $6.5M | $11.5M | 86.6% | 9 |
| 2022 | $5.9M | $4.7M | $9.9M | 80.3% | 6 |
| 2021 | $3.8M | $3.7M | N/A | — | 5 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.